AstraZeneca shares plummet 16% on late-stage trial failure; Bristol-Myers shares fall 6% and Merck shares rise 5% – MarketWatch

AstraZeneca shares plummet 16% on late-stage trial failure; Bristol-Myers shares fall 6% and Merck shares rise 5% – MarketWatch
MarketWatchAstraZeneca shares plummet 16% on late-stage trial failure; Bristol-Myers shares fall 6% and Merck shares rise 5%MarketWatchAstraZeneca PLC AZN, +0.47% shares plummeted as much as 16% in premarket trade Thursday after the company said its cancer drug combination failed to meet its primary endpoint in a late-stage clinical trial. In the AstraZeneca late-stage trial, the …UPDATE 1-Bristol-Myers shares fall after failed AstraZeneca drug trial (BMY, AZN, MRK)Markets Insiderall 59 news articles »
AstraZeneca shares plummet 16% on late-stage trial failure; Bristol-Myers shares fall 6% and Merck shares rise 5% – MarketWatch